Thermo Fisher: A Hold For Stability, Not For Outperformance

Thermo Fisher Scientific is a high-quality, defensive investment with a strong moat but faces revenue growth headwinds and limited upside. Learn more about TMO stock here. Read More

Here’s Why Thermo Fisher Scientific (TMO) Traded Lower in Q2

Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned ... Read More

Thermo Fisher Scientific 2Q Profit, Revenue Rise

Thermo Fisher Scientific posted better-than-expected profit and revenue in its latest quarter. The company, which sells lab equipment, chemicals and tests, among other life-sciences services and ... Read More

Beyond The Numbers: 11 Analysts Discuss Thermo Fisher Scientific Stock

Insights from analysts' 12-month price targets are revealed, presenting an average target of $521.82, a high estimate of $590.00, and a low estimate of $450.00. Surpassing the previous average price ... Read More

Thermo Fisher Scientific (TMO) Tops Q2 Earnings and Revenue Estimates

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.36 per share, beating the Zacks Consensus Estimate of $5.22 per share. This compares to earnings of $5.37 per share a year ago. Read More

Strategic Sale: Joseph R Holmes Decides To Exercise Options Worth $88K At Thermo Fisher Scientific

Currently, Thermo Fisher Scientific shares are trading down 0.77%, priced at $483.79 during Wednesday's morning. This values Holmes's 385 shares at $88,473. Read More

Thermo Fisher Scientific Stock Jumps on Strong Results, Higher Outlook

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ... Read More

Thermo Fisher raises 2025 guidance to $44.2B revenue and $22.84 EPS amid strong pharma and biotech momentum

Casper stated, "We're increasing our guidance for the full year on the top and bottom line. We now expect revenue in the range of $43.6 billion to $44.2 billion, and adjusted EPS in the range of ... Read More

Barclays Upgrades Thermo Fisher Scientific (TMO)

Fintel reports that on September 11, 2025, Barclays upgraded their outlook for Thermo Fisher Scientific (NYSE:TMO) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 18.47% Upside As of ... Read More